CRA evaluates Canadian pharmaceutical pricing

CRA provided expert testimony in multiple proceedings before the Patented Medicine Prices Review Board (PMPRB) in relation to alleged excessive pricing by pharmaceutical companies in Canada. CRA addressed the application of published guidelines by the PMPRB, and the relationship between certain tests described in those guidelines and other means of evaluation whether drug prices are excessive.

Meet Our Team